Rapid sequence induction and intubation with rocuronium–sugammadex compared with succinylcholine: a randomized trial

M. K. Sørensen 1*, C. Bretlau 2, M. R. Gätke 2, A. M. Sørensen 1 and L. S. Rasmussen 1

1 Department of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
2 Department of Anaesthesiology, Copenhagen University Hospital, Herlev Hospital, Herlev Ringvej 75, 2730 Herlev, Denmark
* Corresponding author. E-mail: martin@kryspin.dk

Background. An unanticipated difficult airway may arise during rapid sequence induction and intubation (RSII). The aim of the trial was to assess how rapidly spontaneous ventilation could be re-established after RSII. We hypothesized that the time period from tracheal intubation to spontaneous ventilation would be shorter with rocuronium–sugammadex than with succinylcholine.

Methods. This randomized and patient- and observer-blinded trial was approved by the regional Ethics Committee and the Danish Medicines Agency. We included elective surgical patients undergoing general anaesthesia for RSII using alfentanil (10 μg kg⁻¹), propofol (2 mg kg⁻¹), and either succinylcholine (1 mg kg⁻¹) or rocuronium (1 mg kg⁻¹). Sugammadex (16 mg kg⁻¹) was given in the rocuronium group after tracheal intubation.

The primary endpoint was the time from correct placement of the tracheal tube to spontaneous ventilation, defined as a respiratory rate of more than 8 bpm and a tidal volume of at least 3 ml kg⁻¹ for 30 s.

Results. We included 61 patients; of whom, 55 were evaluated for the primary endpoint. The median time from tracheal intubation to spontaneous ventilation was 406 s with succinylcholine and 216 s with rocuronium–sugammadex (P = 0.002). The median time from tracheal intubation to 90% recovery of the first twitch in train-of-four (T₁ 90%) was 518 s with succinylcholine and 168 s with rocuronium–sugammadex (P < 0.0001).

Intubation conditions and time to tracheal intubation were not significantly different.

Conclusions. RSII with rocuronium followed by reversal with sugammadex allowed earlier re-establishment of spontaneous ventilation than with succinylcholine.

Keywords: anaesthesia, intravenous; intubation, intratracheal; neuromuscular block

Accepted for publication: 23 November 2011

Succinylcholine has been for a long time the NMBA of choice for RSII, because of quick onset along with excellent intubation conditions. However, it has been desirable to identify an alternative to succinylcholine because of its side-effects and the risk of delayed recovery of neuromuscular function. Spontaneous recovery of a succinylcholine-induced neuromuscular block may take too long to avoid desaturation in a ‘cannot intubate, cannot ventilate’ situation. In some patients, the hydrolysis of succinylcholine may be severely impaired as a result of genetic or acquired low cholinesterase activity.

As an alternative to succinylcholine, the non-depolarizing NMBA rocuronium can be used for RSII. The onset time of rocuronium 1 mg kg⁻¹ is around 60 s. Its duration of action is, however, 122 (33) min [from injection to recovery of first twitch of train-of-four (TOF) to 75% of baseline] for a single bolus dose of 0.9 mg kg⁻¹. A new antagonist, sugammadex, binds the rocuronium molecules in a 1:1 ratio without having an effect on the plasma cholinesterase.

© The Author [2012]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
or on any receptor system in the human body.\textsuperscript{10-14} Even profound neuromuscular block with rocuronium can be quickly antagonized with sugammadex.\textsuperscript{15}

The aim of this trial was to assess the time from verified correct tracheal tube placement after RSII until regular and spontaneous ventilation was re-established. In addition, we assessed the intubation conditions and the duration of action of NMBA using acceleromyography. We hypothesized that the time from correct tracheal tube placement to spontaneous ventilation would be shorter with rocuronium followed by sugammadex, than with succinylcholine.

**Methods**

The Danish Medicines Agency and the Regional Ethics Committee approved the trial, which adhered to the standards of the International Conference on Harmonization Good Clinical Practice. The trial (NCT00953550) was registered at ClinicalTrials.gov before inclusion of the first patient. Written informed consent was obtained from all patients participating in this two-centre trial.

The patients were eligible if they were between 18 and 60 yr of age and undergoing RSII. We excluded patients with known allergic reactions to propofol, alfentanil, succinylcholine, rocuronium, or sugammadex, patients undergoing emergency surgery (operation scheduled <24 h), a BMI of above 35 kg m\(^{-2}\), severe renal disease defined by S-creatinine >0.200 mmol litre\(^{-1}\), New York Heart Association Functional Classification above II, a Canadian Cardiovascular Society Functional Classification of Angina above II, potassium >5.0 mmol litre\(^{-1}\), untreated glaucoma, neuromuscular disease, a known disposition for malignant hyperthermia, female patients of child-bearing potential, and breastfeeding women.

**Trial protocol**

Patients were randomized 1:1 according to a computer-generated list (GraphPad QuickCalcs, GraphPad Software\textsuperscript{8}, Inc., La Jolla, CA, USA). A total of 65 sealed and opaque envelopes were prepared for the trial by staff with no other involvement in it. The Regional Ethics Committee approved inclusion until 55 assessable patients for the primary endpoint (time to re-establishment of spontaneous ventilation) were collected, with a maximum of 65 included patients. Thus, enrolment was planned to be stopped when reaching 55 patients where the primary endpoint was assessed. The intervention allocation list was securely stored without access for the investigators, along with an allocation key.

The patients were randomized to receive either succinylcholine (1 mg kg\(^{-1}\)) or rocuronium (1 mg kg\(^{-1}\)) followed by sugammadex (16 mg kg\(^{-1}\)). The investigation was timed in a logged software program TOF-Watch\textsuperscript{8} SX Monitor (Version 2.5 INT 2007, Organon, The Netherlands) from the start of pre-oxygenation.

The patients were monitored with a three-lead ECG, non-invasive arterial pressure measurement, and pulse oximetry. Hypnotic depth was assessed using BIS VISTA\textsuperscript{8}.
operating theatre could not be blinded. Neuromuscular data from 17 patients randomized to the succinylcholine group had their butyrylcholinesterase genotype analysed along with the enzyme activity for another study.

The primary outcome variable was the time from correct placement of the tracheal tube (confirmed by auscultation after intubation) until re-establishment of spontaneous ventilation, defined as a respiratory rate of 8 bpm, a tidal volume above 3 ml kg\(^{-1}\) and an arterial oxygen saturation of above 90%, for 30 s. Tidal volume was measured using the built-in spirometer in the anaesthetic machine.

Secondary outcomes were duration of action of NMBA measured with TOF-Watch\(^{SX}\) from start of injection of the NMBA to recovery of \(T_1\) in TOF to above 90% (\(T_1\) 90%) and from tracheal intubation to recovery of \(T_1\) to 90%. The \(T_1\) 90% value was calculated as 90% of the \(T_1\)-max value, which was the second of three consecutive \(T_1\) values in the TOF, after \(T_1\) had reached a plateau. The \(T_1\)-max value evaluation was done independently by two investigators; in the case of discrepancy, a third investigator judged what observation to report or whether the measurement should be discarded. Intubation difficulty scale (IDS)\(^{18}\) and intubation conditions\(^{16}\) were also assessed. Adverse events were reported by a non-blinded investigator, and the possibility of awareness was evaluated after operation after discharge from the postoperative care unit and again within 24 h after surgery by a modified Brice interview for all randomized patients\(^{19,20}\) along with an assessment of generalized muscle ache.

### Statistical analysis

The sample size calculation was based on a pilot protocol with 10 included patients. The data from the pilot indicated that a presumed standard deviation of 80 s would be realistic for return of spontaneous ventilation. A difference of 60 s in time to spontaneous ventilation was considered to be clinically relevant. Based on this, we calculated a sample size of 55 patients for the primary endpoint, assuming a power of 0.80 at the 5% significance level.

Patient characteristic data and continuous variables were presented as median values (inter-quartile range). The primary endpoint and other continuous variables were compared using the Mann–Whitney rank-sum test. Proportions were compared using a \(\chi^2\) test or Fisher’s exact test. \(P<0.05\) was considered statistically significant. We made an ‘intention to treat’ analysis on all randomized patients who received an intervention using SAS\(^{9.1}\) statistical software version 9.1 (SAS Institute Inc., Cary, NC, USA).

### Results

Between September 2009 and January 2011, we enrolled 61 patients at two centres (Fig. 2). A total of 55 patients were
evaluated in the ‘intention to treat’ analysis. Patient characteristic data are given in Table 1. All patients had an increased risk of aspiration. Two patients were excluded after randomization because of a protocol violation: one due to an unanticipated difficult airway, which resulted in the use of a NMBA out of protocol to re-paralyse the patient, and in the other, a remifentanil infusion was started inadvertently.

The median time from intubation to spontaneous ventilation was 406 s with succinylcholine and 216 s with rocuronium–sugammadex ($P=0.002$, Table 2). The median time from tracheal intubation to $T_1$ 90% was 518 s with succinylcholine and 168 s with rocuronium–sugammadex ($P<0.0001$, Table 2). The median time from injection of NMBA to recovery of $T_1$ 90% was 719 s with succinylcholine and 282 s with rocuronium–sugammadex ($P<0.0001$, Table 2). Eleven patients were not included in the analysis of acceleromyography measurements due to a calibration error (Table 2). Intubation conditions and time to tracheal intubation were not significantly different.

In the succinylcholine group, we observed: desaturation to 80% ($n=1$), bronchospasm ($n=1$), severe generalized
muscle ache (n=2), and unanticipated difficult tracheal intubation, defined by an IDS value above 5 (n=3; one patient excluded after randomization). Adverse events of importance during induction in the rocuronium–sugammadex group were: urticaria in the surgical zone after chlorhexidine application (n=1) and tachycardia to above 100 bpm (n=3). Recall was not suspected in any of the patients within 24 h after operation. No patient has contacted an investigator describing memories or events suggestive of awareness during induction or intraoperatively.

Discussion

We found that spontaneous ventilation was re-established significantly earlier using rocuronium-sugammadex instead of succinylcholine for rapid sequence induction. The difference in the median values was around 3 min, and an even greater difference was found in the recovery of neuromuscular function. The trial was conducted on two well-matched groups of patients undergoing RSII, which was performed in a standardized regimen. The primary endpoint was evaluated by a blinded investigator and the tidal volume of 3 ml kg⁻¹
**Table 2** Tracheal intubation conditions, time to reappearance of a spontaneous ventilation, and recovery of neuromuscular function in surgical patients randomized to either succinylcholine or rocuronium–sugammadex for RSII. Values are median (inter-quartile range), \( n = \) number of patients. The \( T_1 \)-max value was the second value of three consecutive \( T_1 \) values in the TOF, after \( T_1 \) had reached a plateau with little or no further increase in its amplitude. The \( T_1 \) 90% value was calculated as 90% of the \( T_1 \)-max value.

<table>
<thead>
<tr>
<th>Time from start of procedure to tracheal intubation (s)</th>
<th>Intubation difficulty score ( \leq 5 )</th>
<th>( &gt;5 )</th>
<th>Time from tracheal intubation to spontaneous ventilation (s)</th>
<th>Time from tracheal intubation to ( T_1 ) 90% (s)</th>
<th>Time from injection of NMBA to ( T_1 ) 90% (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Succinylcholine (1 mg kg(^{-1})) ( n = 26 )</td>
<td>24 (92%)</td>
<td>2 (8%)</td>
<td>406 (313–507)</td>
<td>518 (451–671) ( n = 17 )</td>
<td>719 (575–787) ( n = 17 )</td>
</tr>
<tr>
<td>Rocuronium (1 mg kg(^{-1})) Sugammadex (16 mg kg(^{-1})) ( n = 29 )</td>
<td>28 (100%)</td>
<td>0 (0%)</td>
<td>216 (132–425)</td>
<td>168 (122–201) ( n = 27 )</td>
<td>282 (242–319) ( n = 27 )</td>
</tr>
<tr>
<td><strong>P-value</strong></td>
<td></td>
<td></td>
<td><strong>P-value</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.45</td>
<td>0.13</td>
<td>0.23</td>
</tr>
</tbody>
</table>

and respiratory rate of 8 bpm kept for 30 s must be considered conservative when concluding the presence of spontaneous ventilation after RSII. We studied patients with increased risk of aspiration and we assessed recovery of spontaneous ventilation, which we consider as a more clinically important endpoint than evaluating recovery of neuromuscular function alone.\(^{15}\)

We included only elective patients. This was done for practical and research ethical reasons since it would be difficult to strictly standardize the anaesthetic procedure in emergency patients who could have compromised haemodynamic status and fluid deficits necessitating a reduction in the propofol and alfentanil doses. Patients with significant heart disease were excluded, and a reduction in the induction dosages would be needed in some of these patients as well. Our findings are not applicable in obese patients, because the intubation dose of rocuronium should not be 1 mg kg\(^{-1}\) according to total body weight.\(^{21}\)

RSII in elderly patients would have to be based on different doses as propofol especially needs to be given in a reduced dose.\(^{22,23}\) A propofol infusion was given after intubation to avoid awareness. This may have prolonged the time to spontaneous ventilation, but we do not suspect that it has caused a difference between the two groups. The tracheal tube kept the airway open, and even little diaphragmatic movement can create airflow in this situation because the diaphragm is relatively resistant to NMBAs.\(^{26}\) This limitation is known to us, but due to ethical considerations, it would not have been possible to leave these research patients in apnoea and not to intubate the trachea because of the risk of aspiration. Another limitation of the study was that onset of spontaneous ventilation could be influenced by even gentle ventilation as this may lower the respiratory drive. The observer was effectively blinded, but onset of spontaneous ventilation was the primary endpoint. Still, we consider this approach appropriate in this clinical trial to avoid desaturation and excessive hypercapnia. In a study aimed at investigating reversal of profound neuromuscular block, when comparing succinylcholine 1.0 mg kg\(^{-1}\) with rocuronium 1.2 mg kg\(^{-1}\) and sugammadex 16 mg kg\(^{-1}\), Lee and colleagues\(^{15}\) demonstrated a recovery to \( T_1 \) 90% in 10.9 min (mean value) from the start of injection of succinylcholine. This is in accordance with our finding of 12.0 min (median value). The automated calibration (CAL2) of the TOF-Watch\(^{10}\) SX was not successful in all patients in our study due to a narrow time frame in which it had to succeed between onset of the hypnotic and of NMBA. If calibration was obstructed or the equipment was defective, this was not known until the algorithm of the procedure was running. We compensated for these errors by re-calibrating the equipment after full recovery of the neuromuscular block in all patients. This was done to verify that the true plateau in the \( T_1 \) values was in fact reached.

In the rocuronium group, intubation conditions tended to be better and a lower IDS was observed. This tendency is in contradiction with the conclusion of a systematic Cochrane review reporting succinylcholine to be superior to rocuronium (all doses) in creating optimal intubation conditions.\(^{4}\) The reason for this discrepancy could be that we used 1 mg kg\(^{-1}\) rocuronium and that the timing of NMBA administration in our study favours rocuronium as the intubation attempt was done as late as 60 s after the drug had been given. The choice of using 1 mg kg\(^{-1}\) rocuronium was based on the recommendation by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine\(^{2}\) and it reflects our practice. All patients received 2 mg kg\(^{-1}\) propofol, which most likely improved intubation conditions when compared with a smaller dose or a different hypnotic. An advantage of using rocuronium is the fact that intubation conditions will be favourable until reversal with sugammadex is initiated.
The most serious adverse effects of succinylcholine are bradycardia, asystole, elevation of the plasma potassium concentration, and malignant hyperthermia. Other adverse effects include muscle ache. Sugammadex has a low incidence of adverse effects and the profile of the adverse events has so far not been serious.

Unassisted spontaneous ventilation in patients administered succinylcholine may not occur sufficiently soon after failed intubation to avoid desaturation. The genotype of the butyrylcholinesterase is known to be of importance for the ability to metabolize succinylcholine. This might explain the variability in time to recover from succinylcholine-induced block. Recent studies have shown that succinylcholine was associated with a more rapid desaturation than rocuronium during RSII. Patients with a BMI that succinylcholine was associated with a more rapid desaturation to 95% has been reported ~7 min after injection of rocuronium 1 mg kg\(^{-1}\) in patients carefully pre-oxygenated and sugammadex should therefore be expected to allow re-establishment of spontaneous ventilation before profound hypoxemia occurs. In our study, however, sugammadex was given much sooner than in a real clinical situation where several tracheal intubation attempts will usually be done before a decision to wake the patient. Our study did not include this delay, but it is difficult to see how a research protocol could reflect an emergency situation in a more realistic way.

The price of an escape bolus of sugammadex (16 mg kg\(^{-1}\)) for a 75 kg patient with intense neuromuscular block is approximately €760 in Denmark. It is an expensive drug, but an escape dose of sugammadex is needed in only very few patients. If the possible complications of prolonged apnoea in a high-risk patient during induction can be avoided, then the cost of the drug is not important. Unanticipated prolonged apnoea will make most anaesthesiologists to begin forced bag-valve ventilation at some point to avoid desaturation, although this increases the risk of aspiration considerably, especially in patients already categorized as being at high risk of aspiration.

The safety of RSII can probably be enhanced when using rocuronium if sugammadex is available as an escape drug. We recommend a strict RSII protocol, where the escape sugammadex dose is calculated, the drug is readily available in the operating theatre, although not drawn up, and syringes are prepared for emergency draw up, before initiation of RSII. In conclusion, RSII with rocuronium followed by sugammadex allowed earlier re-establishment of spontaneous ventilation than with succinylcholine.

Declaration of interest
None declared.

Funding
The study was supported by Trygfonden (Tryg Foundation), Lyngby, Denmark.

References
7 Han TH, Martyn JA. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus. Br J Anaesth 2005; 102: 55–60
17 Bretlau C, Sørensen MK, Vedersoe AL, Rasmussen LS, Gätke MR. Response to succinylcholine in patients carrying the K-variant of the butyrylcholinesterase gene. SSAI Congress, Bergen, June 2011; Abstract 0031
25 Lee C. Goodbye suxamethonium! Anaesthesia 2009; 64(Suppl. 1): 73–81